GlassScriptPhysician profile
Vincent T Cooper
NPI 1336299551
$8,203.78
in general payments reported to CMS, 2019-2025
35 companies · $3,216 in 2025
The $3,216 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $185 · 2021: $41.22 · 2022: $1,005 · 2023: $2,162 · 2024: $826 · 2025: $3,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,123 · Travel and Lodging: $2,071 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,122.83 |
| Travel and Lodging | $2,071.06 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $3,282.63 | 2023-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $508.47 | 2019-2025 | Xtandi, Myrbetriq |
| Medtronic, INC. | $462.73 | 2021-2025 | Interstim |
| Merck Sharp & Dohme LLC | $429.05 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Sumitomo Pharma America, INC. | $365.44 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $343.97 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Pfizer INC. | $325.64 | 2019-2025 | |
| Medtronic USA, INC. | $240.52 | 2019-2020 | |
| Urovant Sciences INC | $235.99 | 2022 | |
| Neotract INC. | $232.45 | 2019 | |
| Abbvie INC. | $214.76 | 2019-2025 | Botox |
| Boston Scientific Corporation | $201.38 | 2019-2025 | Axonics, Ams 700, Spyglass Discover |
| Tolmar, INC. | $197.84 | 2023-2025 | Eligard, Jatenzo |
| Urogen Pharma, INC. | $194.92 | 2023-2024 | Jelmyto |
| 180 Medical, INC. | $188.90 | 2022-2025 | Gentlecath |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $115.35 | 2025 | Adstiladrin |
| Coloplast Corp | $83.97 | 2022-2025 | |
| Intuitive Surgical, INC. | $81.67 | 2019 | |
| Endo USA, INC. | $77.02 | 2025 | Aveed, Xiaflex |
| Axonics, INC. | $43.44 | 2023-2024 | Axonics |
| Amgen INC. | $43.18 | 2019 | |
| Endo Pharmaceuticals INC. | $35.19 | 2019-2023 | Xiaflex, Aveed |
| Rochester Medical Corporation | $34.77 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $29.87 | 2025 | Gore Bio-A Tissue Reinforcement |
| Blue Earth Diagnostics | $29.74 | 2019 | |
| Hollister Incorporated | $25.59 | 2019-2023 | Onli |
| Novartis Pharmaceuticals Corporation | $25.23 | 2024 | |
| Shionogi INC | $25.06 | 2025 | Fetroja |
| Dendreon Pharmaceuticals LLC | $23.06 | 2019 | |
| Antares Pharma, INC. | $22.64 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $19.47 | 2019 | |
| Procept Biorobotics Corporation | $19.42 | 2023 | Aquabeam Robotic System |
| Calyxo, INC. | $18.59 | 2025 | Cvac Aspiration System |
| Agiliti Surgical, INC. | $13.85 | 2023 | Sonablate, Versapulse Powersuite 80w |
| Allergan, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.